Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neratinib + temsirolimus
- Development stage
- Unknown
- Lead developer
- Puma Biotechnology
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Neratinib + temsirolimus is a combination of two small molecule drugs used in oncology research. Neratinib is an irreversible pan-HER tyrosine kinase inhibitor that targets the human epidermal growth factor receptor (HER) family—including HER1 (EGFR), HER2 (ErbB2), and HER4—blocking downstream signaling pathways involved in tumor cell proliferation and survival. Temsirolimus is an inhibitor of mammalian target of rapamycin (mTOR), a key regulator of cell growth and metabolism. The rationale for combining these agents stems from preclinical evidence showing synergy between HER2 inhibition and mTOR inhibition in various cancer models. This combination has been evaluated in phase I clinical trials for patients with advanced solid tumors, including breast cancer resistant to trastuzumab and non-small-cell lung cancer with HER2 mutations. The regimen demonstrated tolerability at specific dose levels and showed antitumor activity across multiple tumor types[1][2][4].
- Brand names
- NerlynxTorisel
- Other names
- neratinib plus temsirolimus
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)mTOR (Mammalian target of rapamycin kinase)EGFR (Epidermal growth factor receptor)ERBB4 (Erb-b2 receptor tyrosine kinase 4)
Beyond the preview
Go deeper on neratinib + temsirolimus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neratinib + temsirolimus.